A new initiative led by Columbia University and the n-Lorem Foundation will develop personalized therapies for individuals with "nano-rare" genetic forms of ALS and treat them for free, for life.
Parkinson’s patients and their families are increasingly turning to genetic testing to learn more about their disease or risk of passing it on. But testing is complex, and counseling is advised.
COVID patients who remain unresponsive after receiving respiratory support may require long time periods to regain consciousness; delays are related to blood oxygen levels.
A new anti-inflammatory drug may offer hope for people with a progressive form of MS. In a phase 2 trial, the drug slowed brain atrophy in people with the disease.
A Mailman study of more than 1 million pregnancies in Finland reports that prenatal exposure to elevated levels of DDT is associated with an increased risk for autism.
A new clinical trial suggests that donepezil does not improve cognitive performance in people with mild cognitive impairment who also have clinical depression.
In one of the first studies of its kind, Columbia’s Philip De Jager shows how "big data" analyses may lead to new treatment strategies for Alzheimer's disease.
Scientists at Columbia University Vagelos College of Physicians and Surgeons present the most definitive evidence to date that the human brain makes new neurons throughout life.